Malignant Neoplasms of Lip Oral Cavity and Pharynx Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0081505 (Malignant Neoplasms of Lip Oral Cavity and Pharynx)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03435952Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NTTreatment